KalVista Pharmaceuticals (NASDAQ:KALV) Stock Rating Reaffirmed by HC Wainwright

KalVista Pharmaceuticals (NASDAQ:KALV)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report released on Monday, Benzinga reports. They currently have a $20.00 price objective on the specialty pharmaceutical company’s stock. HC Wainwright’s target price points to a potential upside of 31.15% from the stock’s previous close.

Separately, Needham & Company LLC reduced their target price on KalVista Pharmaceuticals from $35.00 to $32.00 and set a “buy” rating on the stock in a report on Friday, July 12th.

KalVista Pharmaceuticals Trading Up 1.9 %

KALV stock opened at $15.25 on Monday. KalVista Pharmaceuticals has a 1-year low of $7.21 and a 1-year high of $16.88. The firm has a market cap of $651.79 million, a P/E ratio of -4.49 and a beta of 0.91. The business’s 50 day moving average is $11.98 and its 200-day moving average is $12.50.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Thursday, July 11th. The specialty pharmaceutical company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.29). Sell-side analysts forecast that KalVista Pharmaceuticals will post -2.65 EPS for the current year.

Insiders Place Their Bets

In other KalVista Pharmaceuticals news, insider Edward P. Feener sold 8,088 shares of the company’s stock in a transaction on Monday, May 20th. The stock was sold at an average price of $11.76, for a total transaction of $95,114.88. Following the transaction, the insider now owns 72,858 shares of the company’s stock, valued at approximately $856,810.08. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 21,959 shares of the company’s stock in a transaction on Monday, May 20th. The stock was sold at an average price of $11.76, for a total transaction of $258,237.84. Following the transaction, the chief executive officer now owns 216,387 shares of the company’s stock, valued at approximately $2,544,711.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Edward P. Feener sold 8,088 shares of the company’s stock in a transaction on Monday, May 20th. The shares were sold at an average price of $11.76, for a total transaction of $95,114.88. Following the sale, the insider now owns 72,858 shares of the company’s stock, valued at approximately $856,810.08. The disclosure for this sale can be found here. In the last quarter, insiders have sold 37,512 shares of company stock valued at $439,424. 12.30% of the stock is currently owned by corporate insiders.

Institutional Trading of KalVista Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the business. Frazier Life Sciences Management L.P. raised its position in shares of KalVista Pharmaceuticals by 11.8% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 3,622,294 shares of the specialty pharmaceutical company’s stock valued at $44,373,000 after acquiring an additional 383,435 shares during the last quarter. Vanguard Group Inc. raised its position in shares of KalVista Pharmaceuticals by 9.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,732,489 shares of the specialty pharmaceutical company’s stock valued at $16,684,000 after acquiring an additional 151,808 shares during the last quarter. SG Americas Securities LLC raised its position in shares of KalVista Pharmaceuticals by 5.1% during the 4th quarter. SG Americas Securities LLC now owns 137,817 shares of the specialty pharmaceutical company’s stock valued at $1,688,000 after acquiring an additional 6,670 shares during the last quarter. AJOVista LLC bought a new stake in shares of KalVista Pharmaceuticals during the 4th quarter valued at $60,000. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of KalVista Pharmaceuticals during the 4th quarter valued at $49,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.